Allen Mooney & Barnes Investment Advisors LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 546,663 shares of the company's stock, valued at approximately $11,671,000. Kenvue comprises 2.0% of Allen Mooney & Barnes Investment Advisors LLC's portfolio, making the stock its 18th biggest position.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of Kenvue in the 2nd quarter valued at $412,000. Parallel Advisors LLC raised its holdings in shares of Kenvue by 27.3% in the second quarter. Parallel Advisors LLC now owns 25,936 shares of the company's stock valued at $472,000 after buying an additional 5,558 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Kenvue by 7.0% during the second quarter. Envestnet Asset Management Inc. now owns 5,721,005 shares of the company's stock worth $104,008,000 after buying an additional 375,425 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Kenvue by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 14,923,756 shares of the company's stock worth $271,356,000 after buying an additional 41,488 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. increased its position in Kenvue by 2.0% in the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 36,691 shares of the company's stock valued at $668,000 after acquiring an additional 737 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently weighed in on KVUE. Citigroup lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Jefferies Financial Group started coverage on Kenvue in a report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target for the company. Barclays upgraded Kenvue to a "hold" rating in a research report on Thursday, December 12th. Finally, Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research report on Monday, December 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $23.18.
Read Our Latest Analysis on KVUE
Kenvue Price Performance
Shares of KVUE stock traded down $0.20 during trading hours on Wednesday, hitting $20.83. The company's stock had a trading volume of 10,049,953 shares, compared to its average volume of 9,171,817. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market cap of $39.94 billion, a price-to-earnings ratio of 37.87, a P/E/G ratio of 2.02 and a beta of 1.46. The business has a fifty day moving average of $22.54 and a 200-day moving average of $21.65.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter last year, the business posted $0.31 earnings per share. Kenvue's revenue was down .4% compared to the same quarter last year. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.94%. Kenvue's dividend payout ratio (DPR) is 149.09%.
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
